Identification of immunological and prognostic value of SHROOM2 in pan-cancer and experimental verification of its role in promoting malignant phenotypes in breast cancer.

ABSTRACT:

Objective

This study aimed to investigate the relationship between Shroom Family Member 2 (SHROOM2) expression and immune features, survival outcomes, and tumor mutational burden (TMB) across various cancer types, as well as its impact on the aggressive behavior of breast cancer (BC).

Methods

RNA sequencing and clinical survival data were retrieved from the TCGA-BRCA and TCGA-PANCANCER datasets within The Cancer Genome Atlas (TCGA) database. Survival analyses were performed to assess the association between SHROOM2 expression and clinical outcomes across different cancer types. Gene set enrichment analysis (GSEA) was applied to identify potential mechanisms associated with differentially expressed genes in BC. Spearman correlation and Wilcoxon tests were used to evaluate the

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12476865 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature